Debt-to-equity of Verve Therapeutics, Inc. from 31 Mar 2022 to 31 Mar 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Verve Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 31 Mar 2022 to 31 Mar 2025.
  • Verve Therapeutics, Inc. Debt-to-equity for the quarter ending 31 Mar 2025 was 30%, a 9% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Verve Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q1 2025 30% +2.5% +9% 31 Mar 2025
Q4 2024 29% +1.6% +5.7% 31 Dec 2024
Q3 2024 27% +0.74% +2.8% 30 Sep 2024
Q2 2024 28% +3.6% +15% 30 Jun 2024
Q1 2024 27% +6.1% +29% 31 Mar 2024
Q4 2023 27% +9.9% +57% 31 Dec 2023
Q3 2023 27% +14% +106% 30 Sep 2023
Q2 2023 24% +17% +237% 30 Jun 2023
Q1 2023 21% +15% +244% 31 Mar 2023
Q4 2022 17% 31 Dec 2022
Q3 2022 13% 30 Sep 2022
Q2 2022 7.2% 30 Jun 2022
Q1 2022 6.2% 31 Mar 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.